岡山医学会Acta Medica Okayama0030155812022008第107回 岡山医学会総会251255ENNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008第166回 岡山外科会243250ENNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008第165回 岡山外科会237241ENNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008心臓病センター榊原病院235236ENNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008住友金属鉱山株式会社 住友別子病院233234ENNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008須崎くろしお病院231232ENNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008舌下免疫療法227229ENMitsuhiroOkanoNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008薬物相互作用 (13―下剤の薬物相互作用)223226ENHidekoYokohariMasatoshiOkazakiToshiakiSendoNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008水痘感染妊婦の取り扱い219221ENYujiHiramatsuNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008慢性腎臓病の治療総論 (降圧療法，食事療法を含めて)215218ENTatsuyukiInoueHitoshiSugiyamaHirofumiMakinoNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008XIII 泌尿器科がんにおける標準的治療207213ENMakotoKobukeYasutomoNasuHiromiKumonNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008XII 皮膚がんの診断と標準的治療201206ENMasakiOtsukaKenjiAsagoeKeijiIwatsukiNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008XI 頭頸部がんの標準的治療193200ENSusumuTominagaNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008X 小児悪性腫瘍に対する治療185191ENKosukeChayamaNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008IX 血液疾患最新の治療 ―造血細胞移植療法の進歩―175184ENKatsujiShinagawaNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008非機能性膵内分泌腫瘍の１切除例169173ENYosukeTsunemitsuMasaruInagakiRyosukeHamanoManabuNishieNaoyukiTokunagaShinyaOtsukaToshihideOsakiHiromiIwagakiWe report a rare case of a very large nonfunctioning endocrine tumor of the pancreas without malignant histological features. A 63-year-old woman referred for appetite loss and general fatigue was found to have a tumor in the pancreas head. Computed tomography demonstrated a well-defined pancreatic tumor 45mm in diameter with hypervascular staining in the pancreas head. Angiography showed a hypervascular tumor of the pancreas head and a dilatation of the anterior superior and posterior superior pancreaticoduodenal arteries. The preoperative diagnosis was an endocrine tumor of the pancreas, with undeniable malignancy. Pylorus-preserving pancreaticoduodenectomy was performed. The histopathological diagnosis was a benign nonfunctioning endocrine tumor of the pancreas based on immunohistochemical staining for Chromogranin A, Synaptophysin, and NSE, but not for hormones. The tumor revealed a low labeling index (<2.0%) of Ki-67 indicating its benign character. No tumor recurrence has been identified in the 18 months since surgery.No potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008透析患者における至適血清リン値に関する文献による検討159168ENMakotoTsukijiIn November 2006, The Japanese Society for Dialysis Therapy (JSDT) announced its first guideline, "The guideline for the management of secondary hyperparathyroidism in chronic dialysis patients," which gives the recommended range of management target values, especially for serum phosphorus, corrected serum calcium and serum intact parathyroid hormone concentrations. Recent studies have suggested that these factors are independently associated with mortality, especially increased cardiovascular mortality. In this research we focused on the serum phosphorus concentration because it is the highest clinical factor among these three. We systematically reviewed almost all documents that discussed the relation between serum phosphorus concentration and mortality as well as the "range of the management target value" specified by foreign guidelines from the US, UK, Canada, Australia and other countries. We summarized the finding concerning the serum phosphorus value of dialysis patients (especially the upper bound value). As a result, it was found that the "range of the management target value" varied among these guidelines. The reasons for this variation likely included differences in the measurement day, in the categories of serum phosphorus concentration, and in the exposure conditions among the studies to which the guidelines referred. Moreover, it was concluded that the Japanese guideline announced by the JSDT should be updated based on the results of future studies.No potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008中枢神経疾患に対する成体由来神経幹細胞移植153157ENMasahiroKamedaTetsuroShingoKenichiroMuraokaKazuyaTakahashiTakaoYasuharaIsaoDateNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008内分泌療法再燃前立腺癌に対する HSV-tk 遺伝子発現アデノウイルスベクター及びガンシクロビルを用いた自殺遺伝子治療臨床研究149152ENYasutomoNasu「前立腺癌に対する herpes simplex virus-thymidine kinase遺伝子発現アデノウイルスベクター及びガンシクロビルを用いた遺伝子治療臨床研究」を実施した．対象となる被験者は内分泌療法中に再燃してきた臨床的に遠隔転移を認めない局所再燃前立腺癌とした．まず herpes simplex virus-thymidine kinase（HSV-tk）遺伝子発現アデノウイルスベクターを単独で腫瘍内に直接投与し，その後ガンシクロビル（ganciclovir：GCV）を全身投与した．
本研究は2001年3月より第1例目の被験者の治療を開始し，平成17年7月に最終登録例である9例目の被験者の治療を実施し，6ヶ月以上観察し，臨床試験を終了とした（8名のべ9症例）．
9症例すべてにおいて有意な副作用を認めなかった．また，ウイルスベクター投与後の抗アデノウイルス中和抗体価の上昇は軽度でかつ一過性であった．ウイルスベクター投与後，48時間において採取した組織において ｍRNA レベルでの HSV-tk 遺伝子の発現が確認された．治療効果の指標として腫瘍マーカーである PSA は9例中6例において低下した．
結論として局所再燃前立腺癌に対し，HSV-tk 遺伝子発現アデノウイルスベクターを単独で局所内投与し，その後ガンシクロビルを全身投与することの安全性および治療効果が確認された．No potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008マクロファージスカベンジャー受容体（SR-A）は炎症を制御することにより糖尿病性腎症を抑制する143147ENHitomiKataokaKenichiShikataMotofumiSasakiHirofumiMakinoNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama0030155812022008アデノウイルスベクターを用いた REIC/Dkk-3遺伝子導入による前立腺癌の転移抑制効果について135141ENKoheiEdamuraNo potential conflict of interest relevant to this article was reported.岡山医学会Acta Medica Okayama003015581202200811Rを用いた脳血管に対する新しい蛋白質導入法129133ENTomoyukiOgawaShigekiOnoTomotsuguIchikawaSeijiArimitsuKeisukeOnodaKojiTokunagaKenjiSugiuKazuhitoTomizawaHidekiMatsuiIsaoDateNo potential conflict of interest relevant to this article was reported.